What daily dose of insulin glargine (Lantus) should be ordered for a patient transitioning from a Glucommander insulin pump?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 12, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Transitioning from Glucommander to Lantus: Dosing Protocol

Calculate Initial Lantus Dose Using 24-Hour IV Insulin Total

The starting dose of Lantus should be 50% of the total 24-hour intravenous insulin infusion amount administered via Glucommander. 1

Step-by-Step Calculation Method

  • Add up the total units of IV insulin infused over the previous 24 hours from the Glucommander pump 1
  • Divide this total by 2 to determine the initial once-daily subcutaneous Lantus dose 1
  • Administer Lantus subcutaneously once daily at the same time each day (typically evening or bedtime) 2
  • Continue the IV insulin infusion for at least 2 hours after the first Lantus injection to ensure adequate basal coverage during the transition period 3

Example Calculation

If a patient received 48 units of IV insulin over 24 hours via Glucommander:

  • Initial Lantus dose = 48 units ÷ 2 = 24 units once daily 1

Critical Timing Considerations

Do not discontinue the Glucommander IV insulin immediately after giving the first Lantus injection. The subcutaneous absorption of Lantus requires 2–4 hours to establish steady-state basal coverage, so premature discontinuation of IV insulin will cause rapid insulin deficiency and hyperglycemia 3.

  • Overlap IV and subcutaneous insulin for a minimum of 2 hours after the first Lantus dose 3
  • For patients with Type 1 diabetes or LADA, maintain IV insulin overlap for up to 4 hours to prevent ketosis 4

Prandial Insulin Requirements

Lantus provides only basal (background) insulin coverage and does not address meal-related glucose excursions. 5, 2

If Patient Is Eating

  • Calculate the remaining 50% of the 24-hour IV insulin total and distribute it as rapid-acting insulin (lispro, aspart, or glulisine) before meals 6
  • Divide the prandial insulin into three equal doses given before breakfast, lunch, and dinner 6
  • Using the example above: 48 units total ÷ 2 = 24 units for prandial coverage → 8 units rapid-acting insulin before each meal 6

If Patient Is NPO or on Tube Feeds

  • Continue basal Lantus at 50% of the 24-hour IV total 6, 1
  • Administer correctional rapid-acting insulin every 4–6 hours using an insulin-resistant correction scale (1 unit per 25 mg/dL above target of 150 mg/dL) 6, 4
  • Do not rely on sliding-scale insulin alone—scheduled basal insulin must be maintained even when NPO to prevent ketosis in Type 1 diabetes 6, 4

Dose Titration After Transition

Adjust the Lantus dose every 2–3 days based on fasting blood glucose measurements. 5, 7

  • Target fasting glucose: 100–130 mg/dL (5.6–7.2 mmol/L) 5
  • If fasting glucose >180 mg/dL: increase Lantus by 4 units (or 10–20% of current dose) 5, 7
  • If fasting glucose 140–180 mg/dL: increase Lantus by 2 units (or 10% of current dose) 5, 7
  • If fasting glucose 110–139 mg/dL: increase Lantus by 1 unit 7
  • If hypoglycemia <70 mg/dL occurs: reduce Lantus by 10–20% 5, 7
  • If severe hypoglycemia <40 mg/dL occurs: reduce Lantus by 20–40% 7

Common Pitfalls to Avoid

Pitfall 1: Using 100% of IV Insulin as Lantus Dose

This is the most dangerous error. Using the full 24-hour IV insulin total as the Lantus dose will cause severe hypoglycemia because Lantus provides only basal coverage, whereas IV insulin was covering both basal and prandial needs 6, 1. Always use 50% for basal (Lantus) and 50% for prandial (rapid-acting) insulin 6.

Pitfall 2: Abrupt Discontinuation of IV Insulin

Stopping the Glucommander immediately after giving Lantus will cause rebound hyperglycemia because subcutaneous insulin takes 2–4 hours to reach therapeutic levels 3. Always overlap IV and subcutaneous insulin for at least 2 hours 3.

Pitfall 3: Omitting Prandial Insulin in Eating Patients

Lantus alone will not control postprandial glucose excursions. Patients who are eating require rapid-acting insulin before meals in addition to basal Lantus 5, 2. Failure to provide prandial insulin results in persistent hyperglycemia despite adequate basal coverage 8.

Pitfall 4: Relying on Sliding-Scale Insulin Alone

Sliding-scale insulin as monotherapy leads to poor glycemic control and worse outcomes 6, 4. Correctional insulin should supplement—not replace—scheduled basal and prandial insulin 6.

Special Populations

Elderly or Renally Impaired Patients

  • Start with a more conservative dose: 0.1–0.2 units/kg body weight instead of 50% of IV insulin total 6
  • Use the insulin-sensitive correction scale (lower correction doses) 6
  • Monitor closely for hypoglycemia and reduce doses by 10–20% at the first sign of low glucose 5, 6

Patients on High-Dose Glucocorticoids

  • The 50% rule may underestimate insulin needs in steroid-induced hyperglycemia 4
  • Consider using 60–70% of the 24-hour IV total as Lantus if the patient is on prednisone ≥40 mg daily or equivalent 4
  • Use the insulin-resistant correction scale (higher correction doses) 6, 4

Monitoring Requirements

Check capillary blood glucose before each meal and at bedtime during the first 48–72 hours after transition 6, 1. Pay special attention to:

  • Fasting glucose (reflects adequacy of Lantus dose) 5, 7
  • Pre-lunch, pre-dinner, and bedtime glucose (reflects adequacy of prandial insulin doses) 6
  • Overnight glucose (2–3 AM check if nocturnal hypoglycemia is suspected) 5

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.